Abstract
Among human immunodeficiency virus-positive women in Botswana on the recommended first-line antiretroviral therapy regimen, tenofovir-emtricitabine-efavirenz, initiated within the first or early second trimester, we found no increased risk of stillbirth, neonatal death, preterm/very preterm delivery, or the infant being born small or very small for gestational age. Treatment with tenofovir-emtricitabine-efavirenz <1 year before conception increased the risk of preterm delivery slightly over late-second-trimester treatment initiation (adjusted risk ratio, 1.33 [95% confidence interval, 1.04-1.70]).
MeSH terms
-
Alkynes
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / adverse effects*
-
Benzoxazines / administration & dosage
-
Benzoxazines / adverse effects
-
Botswana
-
Cyclopropanes
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Emtricitabine / administration & dosage
-
Emtricitabine / adverse effects
-
Female
-
Fetal Death
-
Gestational Age*
-
HIV Infections / drug therapy*
-
HIV Infections / transmission
-
Humans
-
Infant, Low Birth Weight
-
Infectious Disease Transmission, Vertical / prevention & control
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Outcome*
-
Premature Birth
-
Stillbirth
-
Tenofovir / administration & dosage
-
Tenofovir / adverse effects
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Tenofovir
-
Emtricitabine
-
efavirenz